Case report details abrupt complications from bosutinib in a CML patient, suggesting toxicity risks may exceed prior assumptions.
This case study outlines the complex treatment journey of a 53-year-old male diagnosed with Chronic Myeloid Leukemia (CML). Despite initial therapy with Imatinib and a subsequent switch to Dasatinib and then Bosutinib due to treatment resistance and adverse effects, the patient experienced multiple unexpected complications, including bilateral pleural effusions, pulmonary arterial hypertension, renal impairment, and neurological symptoms. Bosutinib was identified as the likely cause, leading to its discontinuation and transition to Nilotinib, which resulted in a sustained molecular response without further adverse events. Through this case report and literature review, we aim to expand the dimensions of the toxicity profile of bosutinib.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: